Inupadenant hydrochloride

Cat. No.: HY-137442A

CAS No.: 2411004-22-1

Molecular Formula: $C_{25}H_{27}ClF_2N_8O_4S_2$

Molecular Weight: 641.11

Target: Adenosine Receptor

Pathway: GPCR/G Protein

Storage: 4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 5 mg/mL (7.80 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Concentration / Solvent / Mass	1 mg	5 mg	10 mg
	1 mM	1.5598 mL	7.7990 mL	15.5979 mL
	5 mM	0.3120 mL	1.5598 mL	3.1196 mL
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 0.5 mg/mL (0.78 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 0.5 mg/mL (0.78 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 0.5 mg/mL (0.78 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Inupadenant (EOS-850) hydrochloride is an orally active, highly selective A_{2A} receptor antagonist. Inupadenant hydrochloride is not brain-penetrant. Inupadenant hydrochloride has potent anti-tumor activity[1].

CUSTOMER VALIDATION

- Patent. US20230159541A1.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Laurence Buisseret, et al. Phase 1 trial of the adenosine A2Areceptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A2A receptor within the tumor. Journal of Clinical Oncology. Volume 39, Issue 15_suppl.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA